powder and solution for\u00a0injection, solution
Vaccine against group A, C, W-135, and Y meningococcal infection, conjugated<\/p>\n\n\n\n
Menveo is a vaccine for active immunization of children (from 2 years of age), adolescents, and adults who are at risk of being exposed to a\u00a0bacterium\u00a0called\u00a0Neisseria meningitides\u00a0serogroup A, C, W-135 and Y, to prevent\u00a0invasive\u00a0disease.\u00a0The vaccine works by allowing your body to make its protection (\u00a0antibodies\u00a0) against these bacteria.<\/p>\n\n\n\n
The bacterium\u00a0Neisseria meningitides<\/em>\u00a0group A, C, W-135, and Y can cause serious and sometimes life-threatening\u00a0infections\u00a0such as\u00a0meningitis\u00a0and sepsis.<\/p>\n\n\n\n Menveo cannot cause bacterial\u00a0meningitis.\u00a0This vaccine contains a\u00a0protein\u00a0(called CRM\u00a0197\u00a0) from the bacterium that causes\u00a0diphtheria.\u00a0Menveo does not protect against\u00a0diphtheria.\u00a0This means that you (or your child) should take other vaccines to protect against\u00a0diphtheria\u00a0when needed or when your doctor recommends it.<\/p>\n\n\n\n Talk to your doctor or nurse before you or your child receive Menveo about you or your child<\/p>\n\n\n\n Fainting, fainting, or other stress-related reactions may occur as a reaction to needle sticking.\u00a0Tell your doctor or nurse if you have ever experienced this type of reaction.<\/p>\n\n\n\n This vaccine only protects against meningococcal bacteria groups A, C, W-135, and Y. It does not protect against other types of meningococcal bacteria than groups A, C, W-135, and Y or other causes of\u00a0meningitis\u00a0or\u00a0sepsis.<\/p>\n\n\n\n As with all vaccines, Menveo may not protect 100% of those vaccinated.<\/p>\n\n\n\n If you or your child received a dose of Menveo more than a year ago and are still at particular risk of being exposed to group A meningococcal bacteria, you may want to consider a booster dose to maintain protection. Your doctor will advise if and when you should receive a booster dose.<\/p>\n\n\n\n Tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n Menveo can be given at the same time as other vaccinations, but other injected vaccines should preferably be given in the other arm than the one in which Menveo is injected.<\/p>\n\n\n\n These include the following vaccines: tetanus vaccine,\u00a0diphtheria\u00a0(reduced) and pertussis (acellular, Tdap), human papillomavirus (HPV) vaccine, yellow fever,\u00a0typhoid fever\u00a0(Vi polysaccharide), Japanese\u00a0encephalitis, rabies,\u00a0hepatitis\u00a0A and B vaccine, and\u00a0meningococcal\u00a0group B (Bexsero).<\/p>\n\n\n\n The effect of Menveo can be reduced if given to people taking medicines that reduce the immune system.<\/p>\n\n\n\n Separate injection sites must be selected if more than one vaccine is to be administered at the same time.<\/p>\n\n\n\n If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.\u00a0Your doctor or nurse may still recommend Menveo if there is an increased risk of\u00a0infection\u00a0with meningococcal bacteria groups A, C, W-135, and Y.<\/p>\n\n\n\n No studies have been performed on the ability to drive or use machines.<\/p>\n\n\n\n Dizziness has in very rare cases been reported after vaccination. This may temporarily affect the ability to drive or use machines.<\/p>\n\n\n\n This medicine contains less than 1 mmol\u00a0sodium\u00a0(23 mg) per\u00a0dose, ie essentially ‘sodium-free’.\u00a0is next to “sodium-free”.<\/p>\n\n\n\n This medicine contains less than 1 mmol\u00a0potassium\u00a0(39 mg) per\u00a0dose, ie essentially ‘potassium’.\u00a0is next to “potassium-free”.<\/p>\n\n\n\n Menveo will be given to you or your child by a doctor or nurse.<\/p>\n\n\n\n The vaccine is normally given in the upper arm muscle (deltoid muscle) for children (from 2 years), adolescents, and adults.\u00a0Your doctor or nurse will make sure that the vaccine is not given into a blood vessel and that an\u00a0injection\u00a0is given into a muscle and not into the skin.<\/p>\n\n\n\n For children (from 2 years), adolescents, and adults: a single (0.5 ml)\u00a0injection\u00a0is given.<\/p>\n\n\n\n The safety and efficacy of Menveo in children under 2 years of age have not yet been established.<\/p>\n\n\n\n There is limited data for people between 56 and 65 years and there is no data for people older than 65 years.<\/p>\n\n\n\n Tell your doctor if you have previously received an injection of Menveo or any other meningococcal vaccine. Your doctor will then tell you if you need another injection of Menveo.<\/p>\n\n\n\n For more information on\u00a0the reconstitution\u00a0of the vaccine, please read the section for healthcare professionals at the end of this leaflet.<\/p>\n\n\n\n If you have any further questions on the use of this product, ask your doctor or nurse.<\/p>\n\n\n\n Like all medicines, this medicine can cause\u00a0side effects, although not everybody gets them.<\/p>\n\n\n\n The most common adverse reactions reported in clinical trials usually lasted only one or two days and were not normally severe.<\/p>\n\n\n\n The adverse reactions reported in children (2 to 10 years of age) during clinical trials are reported below.<\/p>\n\n\n\n Very common (may affect more than 1 in 10 people): drowsiness, headache, irritability, general malaise, injection site pain, injection site redness (50 mm or less), injection site hardness (50 mm or less).<\/p>\n\n\n\n Common (may affect less than 1 in 10 people): changes in eating habits, nausea, vomiting, diarrhea, rash, muscle aches, joint pain, chills, fever 38 \u00b0 C or higher, redness at the injection site (greater than 50 mm), hardness at the injection site ( larger than 50 mm).<\/p>\n\n\n\n Uncommon (may affect less than 1 in 100 people): itching at the injection site.<\/p>\n\n\n\n The most common adverse reactions reported in adolescents (from 11 years of age) and adults during clinical trials are reported below.<\/p>\n\n\n\n Very common: headache, nausea, injection site pain, injection site redness (50 mm or less), injection site hardness (50 mm or less), muscle aches, general malaise.<\/p>\n\n\n\n Common: rash, redness at the injection site (greater than 50 mm), hardness at the injection site (greater than 50 mm), joint pain, fever 38 \u00b0 C or higher, chills.<\/p>\n\n\n\n Uncommon: dizziness, itching at the injection site.<\/p>\n\n\n\n Side effects that have been reported after the product became available for sale are:<\/p>\n\n\n\n Rare: enlarged lymph nodes<\/p>\n\n\n\n Not known frequency: allergic reactions which may include severe swelling of the lips, mouth, and throat (which may cause difficulty in swallowing), difficulty in breathing followed by wheezing or coughing, rash and swelling of hands, feet, and ankles, unconsciousness, very low\u00a0blood pressure, seizures (convulsions) including febrile seizures, balance problems, fainting, skin\u00a0infection\u00a0at the injection site, swelling at the injection site, including extensive swelling in the limb where the\u00a0injection\u00a0was given.<\/p>\n\n\n\n If a serious allergic reaction occurs, inform your doctor immediately or go to \/ take your child to the nearest emergency room as emergency care may be needed.<\/p>\n\n\n\n Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiration date is the last day of the specified month.<\/p>\n\n\n\n Store in a refrigerator (2 \u00b0 C – 8 \u00b0 C). Do not freeze. Store the vials in the outer carton.<\/p>\n\n\n\n Sensitive to light.<\/p>\n\n\n\n After\u00a0reconstitution, the product should be used immediately.\u00a0However, chemical and physical in-use stability was demonstrated 8 hours after reconstitution at a temperature below 25 \u00b0 C.<\/p>\n\n\n\n Medicines should not be disposed of via wastewater or household waste. Your doctor or nurse will be responsible for disposing of this medicine. These measures will help to protect the environment.<\/p>\n\n\n\n One dose (0.5 ml of the reconstituted vaccine) contains:<\/p>\n\n\n\n The active substances are<\/p>\n\n\n\n The other ingredients are<\/p>\n\n\n\n In the powder: potassium dihydrogen phosphate and sucrose.<\/p>\n\n\n\n In the liquid: sodium chloride, sodium dihydrogen phosphate monohydrate, sodium hydrogen phosphate dihydrate, and water for injections (see also the end of section 2).<\/p>\n\n\n\n Menveo is a powder and solvent for solution for injection<\/p>\n\n\n\n Each dose of Menveo is delivered in the form of:<\/p>\n\n\n\n Not all pack sizes may be marketed.<\/p>\n\n\n\n The contents of the two components ( vial and vial ) are mixed before vaccination to give a dose of 0.5 ml.<\/strong><\/p>\n\n\n\n Marketing Authorisation Holder:<\/p>\n\n\n\n GSK Vaccines Srl,<\/p>\n\n\n\n Via Fiorentina 1, 53100 Siena,<\/p>\n\n\n\n Italy<\/p>\n\n\n\n Manufacturer:<\/p>\n\n\n\n GSK Vaccines Srl,<\/p>\n\n\n\n Bellaria \u2011 Rosia, 53018 Sovicille (Siena),<\/p>\n\n\n\n Italy<\/p>\n\n\n\n Menveo is a vaccine for active immunization of children (from 2 years of age), adolescents and adults who are at risk of being exposed to a bacterium called Neisseria meningitidis serogroup A, C, W-135 and Y, to prevent invasive disease. The vaccine works by allowing your body to make its own protection ( antibodies ) against these bacteria.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,15580],"tags":[17011,17006,17009,17012,17010,17013,2356,17007,17008],"class_list":["post-17570","post","type-post","status-publish","format-standard","hentry","category-medicines","category-m","tag-benefits-of-menveo","tag-menveo","tag-menveo-caccine","tag-menveo-dosage","tag-menveo-sie-effects","tag-menveo-usage","tag-vaccine","tag-what-is-menveo","tag-what-menveo-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/17570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=17570"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/17570\/revisions"}],"predecessor-version":[{"id":17596,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/17570\/revisions\/17596"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=17570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=17570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=17570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What you need to know before you or your child receive Menveo<\/h2>\n\n\n\n
Do not use Menveo if you or your child<\/h2>\n\n\n\n
Warnings and cautions<\/h2>\n\n\n\n
Other medicines and Menveo<\/h2>\n\n\n\n
Pregnancy, breastfeeding and fertility<\/h2>\n\n\n\n
Driving and using machines<\/h2>\n\n\n\n
Menveo contains<\/h2>\n\n\n\n
How to use Menveo<\/h2>\n\n\n\n
Possible side effects<\/h2>\n\n\n\n
How to store Menveo<\/h2>\n\n\n\n
Contents of the pack and other information<\/h2>\n\n\n\n
Content declaration<\/h2>\n\n\n\n
(Originally in the powder)<\/td> <\/td><\/tr> Meningococcal group<\/em>\u00a0A\u00a0oligosaccharide conjugated to\u00a0Corynebacterium\u00a0diphtheriae<\/em>\u00a0CRM\u00a0197\u00a0<\/sub>protein<\/td> 10 micrograms between 16.7 and 33.3 micrograms<\/td><\/tr> (Originally in the liquid)<\/td> <\/td><\/tr> Meningococcal group<\/em>\u00a0C\u00a0oligosaccharide conjugated to\u00a0Corynebacterium\u00a0diphtheriae<\/em>\u00a0CRM\u00a0197\u00a0<\/sub>protein<\/td> 5 micrograms between 7.1 and 12.5 micrograms<\/td><\/tr> Meningococcal group<\/em>\u00a0W-135\u00a0oligosaccharide conjugated to\u00a0Corynebacterium\u00a0diphtheriae<\/em>\u00a0CRM\u00a0197\u00a0<\/sub>protein<\/td> 5 micrograms between 3.3 and 8.3 micrograms<\/td><\/tr> Meningococcal group<\/em>\u00a0Y\u00a0oligosaccharide conjugated to\u00a0Corynebacterium\u00a0diphtheriae<\/em>\u00a0CRM\u00a0197\u00a0<\/sub>protein<\/td> 5 micrograms between 5.6 and 10.0 micrograms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n What the medicine looks like and contents of the pack<\/h2>\n\n\n\n
Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n
Belgium \/ Belgique \/ Belgien<\/strong>GlaxoSmithKline Pharmaceuticals SA \/ NVTel: + 32 10 85 52 00<\/td> Lithuania<\/strong>GSK Vaccines SrlTel: +370 80000334<\/td><\/tr> Bulgaria<\/strong>GSK Vaccines SrlTel. +359 80018205<\/td> Luxembourg \/ Luxemburg<\/strong>GlaxoSmithKline Pharmaceuticals SA \/ NVTel: + 32 10 85 52 00<\/td><\/tr> Czech Republic<\/strong>GlaxoSmithKline sroTel: + 420 2 22 00 11 11cz.info@gsk.com<\/td> Hungary<\/strong>GSK Vaccines SrlTel .: +36 80088309<\/td><\/tr> Denmark<\/strong>GlaxoSmithKline Pharma A \/ STel: + 45 36 35 91 00dk-info@gsk.com<\/td> Malta<\/strong>GSK Vaccines SrlTel: +356 80065004<\/td><\/tr> Germany<\/strong>GlaxoSmithKline GmbH & Co. KGTel: +49 (0) 89 36044 8701de.impfservice@gsk.com<\/td> The Netherlands<\/strong>GlaxoSmithKline BVTel: + 31 (0) 33 2081100<\/td><\/tr> Eesti<\/strong>GSK Vaccines SrlTel: +372 8002640<\/td> Norway<\/strong>GlaxoSmithKline ASTel: + 47 22 70 20 00<\/td><\/tr> Greece<\/strong>GlaxoSmithKline A\u03bf\u03bd\u03bf\u03c0\u03c1\u03cc\u03c3\u03c9\u03c0\u03b7 AEBET\u03b7\u03bb: + 30 210 68 82 100<\/td> Austria<\/strong>GlaxoSmithKline Pharma GmbH.Tel: + 43 (0) 1 97075 0at.info@gsk.com<\/td><\/tr> Spain<\/strong>GlaxoSmithKline, SATel: + 34 900 202 700es-ci@gsk.com<\/td> Poland<\/strong>GSK Services Sp. z ooTel .: + 48 (22) 576 9000<\/td><\/tr> France<\/strong>GlaxoSmithKline LaboratoryTel: + 33 (0) 1 39 17 84 44diam@gsk.com<\/td> Portugal<\/strong>GlaxoSmithKline – Pharmaceutical Products, Lda.Tel: + 351 21 412 95 00FI.PT@gsk.com<\/td><\/tr> Croatia<\/strong>GSK Vaccines SrlTel .: +385 800787089<\/td> Romania<\/strong>GSK Vaccines SrlTel: +40 800672524<\/td><\/tr> Ireland<\/strong>GlaxoSmithKline (Ireland) LtdTel: + 353 (0) 1 495 5000<\/td> Slovenia<\/strong>GSK Vaccines SrlTel: +386 80688869<\/td><\/tr> Iceland<\/strong>Vistor hf.Phone: +354 535 7000<\/td> Slovak Republic<\/strong>GSK Vaccines SrlTel: +421 800500589<\/td><\/tr> Italy<\/strong>GlaxoSmithKline SpATel: +39 (0) 45 7741 111<\/td> Finland \/ Finland<\/strong>GlaxoSmithKline OyPuh \/ Tel: + 358 10 30 30 30<\/td><\/tr> .\u03a0\u03c1\u03bf\u03c2<\/strong>GSK Vaccines Srl:\u0397\u03bb: +357 80070017<\/td> Sweden<\/strong>GlaxoSmithKline ABTel: + 46 (0) 8 638 93 00info.produkt@gsk.com<\/td><\/tr> Latvia<\/strong>GSK Vaccines SrlTel: +371 80205045<\/td> United Kingdom (Northern Ireland)<\/strong>GSK Vaccines SrlTel: + 44 (0) 800 221 441customercontactuk@gsk.com<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"